Business
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP
About this update from Erasca, Inc.
[{"type":"text","content":"The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent and Trademark Office has issued Patent No. 12,552,813, titled “Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof.” The patent claims protect the composition of matter for Erasca’s potentially first-in-class pan-KRAS inhibitor ERAS-4001 and related compositions until June 2043, which may be subject to patent term adjustments or extensions affording even later protection. “This newly issued U.S. patent strengthens our ERAS-4001 program, builds on the momentum of our RAS franchise which includes our potential first-in-class pan-KRAS inhibitor ERAS-4001 and our potential best-in-class pan-RAS molecular glue ERAS-0015, and advances our diversified intellectual property (IP) strategy in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “With patent protection extending through at least 2043, the ERAS-4001 program is supported by a robust, long-term IP foundation, with additional patents pending. As both RAS-targeting molecules continue to advance rapidly in the clinic, we look forward to reporting Phase 1 data for ERAS-0015 in the first half of the year and for ERAS-4001 in the second half of the year.” About ERAS-4001ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor with a potential first-in-class and best-in-class profile. Erasca is evaluating ERAS-4001 in the BOREALIS-1 Phase 1 trial in patients with KRAS-mutant solid tumors. ERAS-4001 demonstrated favorable preclinical in vitro potency against KRAS G12X mutations as well as KRAS wildtype amplifications, which may limit treatment resistance mediated through KRAS wildtype activation. No activity was observed for ERAS-4001 against HRAS or NRAS wildtype proteins in preclinical studies, which may enable a better therapeutic window compared to pan-RAS inhibitors. ERAS...